Empower Clinics and Pharmachoice Partner to Offer Kai Care Testing
Empower Clinics Inc. (OTCQB:EPWCF) has partnered with Pharmachoice for a six-month pilot program to distribute Kai Care COVID-19 Testing Solutions at over 900 pharmacies across Canada. The MOU aims to evaluate revenue and marketing opportunities while providing approved COVID-19 testing products, including Rapid Antigen, Rapid Antibody, and Saliva RT-PCR tests. CEO Steven McAuley highlights this as a crucial step in enhancing consumer access to testing solutions, with further collaborations expected with major pharmacy networks.
- Partnership with Pharmachoice allows distribution of COVID-19 testing solutions to over 900 Canadian pharmacies.
- Six-month pilot program to evaluate revenue and marketing opportunities.
- Potential for expansion and collaborations with other major pharmacy networks.
- None.
The program to provide COVID-19 Testing Solutions to 900 Pharmacies across Canada
VANCOUVER, BC / ACCESSWIRE / June 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - has signed a Memorandum of Understanding ("MOU") for a six-month pilot program between Empower and Pharmachoice for distribution and resale of Kai Care COVID-19 Testing Solutions. The products will include Rapid Antigen Testing, Rapid Antibody Testing and Saliva RT-PCR tests.
"The expansion to Pharmachoice's network is a phenomenal step forward in our plan to provide Kai Care Testing solutions directly and conveniently to consumers" stated Steven McAuley, Chairman and CEO of Empower Clinics. "We are excited to build on this progress through our ongoing advanced conversations with other major pharmacy groups from across North America."
Pharmachoice is a fast growing, independently owned Canadian Pharmacy network with more than 900 locations covering the PharmaChoice and RxHealthMed brands. Pharmachoice has an impressive network of over 2,000 pharmacists with nearly two decades of experience as a company. The company's local ties across numerous regions make it a great partner in providing direct consumer sales of Kai Care Testing Solutions.
Under the MOU, Pharamchoice and Empower agree to a six-month pilot program to allow both parties to fully evaluate revenue, marketing and partnership expansion opportunities. It is the goal for this period to determine the optimal business model that will best serve PharmaChoice and their patients. Empower will provide Pharmachoice with Health Canada Approved COVID-19 Testing Solutions (Rapid Antigen Testing, Rapid Antibody Testing and Kai Saliva RT-PCR tests), express shipping on all ordered units, and technical support.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO s.mcauley@empowerclinics.com
604-789-2146
Investors:
Tamara Mason
Business Development & Communications t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that Air Canada will successfully refer travelers to Kai Care; that a pilot program with PharmaChoice will be successfulthat legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion in 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/652426/Empower-Clinics-and-Pharmachoice-Partner-to-Offer-Kai-Care-Testing
FAQ
What is Empower Clinics' partnership with Pharmachoice about?
What types of COVID-19 tests will be provided under the Empower and Pharmachoice partnership?
How many pharmacies are involved in the Empower Clinics and Pharmachoice pilot program?
What is the goal of the pilot program between Empower Clinics and Pharmachoice?
What is the significance of this partnership for Empower Clinics (EPWCF)?
